Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.

Kitano D, Chiku M, Li Y, Okumura Y, Fukamachi D, Takayama T, Hiro T, Saito S, Hirayama A.

Cardiovasc Diabetol. 2013 Jun 19;12:92. doi: 10.1186/1475-2840-12-92.

2.

Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.

Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, Mizuguchi T, Motodi Y, Iwasaki M, Taira K, Okamoto H, Matsuo Y, Kim SK, Takarada A, Yokoyama M.

Am J Cardiol. 2012 Jan 1;109(1):42-6. doi: 10.1016/j.amjcard.2011.08.005. Epub 2011 Sep 23.

PMID:
21944671
3.
4.

Drug therapy of postprandial hyperglycaemia.

Mooradian AD, Thurman JE.

Drugs. 1999 Jan;57(1):19-29. Review.

PMID:
9951949
5.
6.

Impaired digital reactive hyperemia and the risk of restenosis after primary coronary intervention in patients with acute coronary syndrome.

Yamamoto M, Hara H, Moroi M, Ito S, Nakamura M, Sugi K.

J Atheroscler Thromb. 2014;21(9):957-65. Epub 2014 May 9.

7.

Postprandial hyperglycemia in patients with type 2 diabetes mellitus.

Sudhir R, Mohan V.

Treat Endocrinol. 2002;1(2):105-16. Review.

PMID:
15765626
8.

Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.

Singh KP, Periyandavar I, Rajadhyaksha GC, Jayaram S, Mishra AB, Kinagi S, Sharma A, Baliga VP.

J Indian Med Assoc. 2007 Jun;105(6):344, 346, 350.

PMID:
18232183
9.

Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.

Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, Kawamori R, Hirose T.

Metabolism. 2008 Sep;57(9):1299-306. doi: 10.1016/j.metabol.2008.04.027.

PMID:
18702958
10.

Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease.

Sawada T, Shiotani H, Terashita D, Nagasawa Y, Kim SS, Koide M, Yokoyama M.

Circ J. 2014;78(1):248-55. Epub 2013 Nov 13.

11.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
13.

Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.

Uzu T, Yokoyama H, Itoh H, Koya D, Nakagawa A, Nishizawa M, Maegawa H, Yokomaku Y, Araki S, Abiko A, Haneda M.

Clin Exp Nephrol. 2011 Feb;15(1):58-63. doi: 10.1007/s10157-010-0343-7. Epub 2010 Sep 9.

PMID:
20824296
14.

Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.

Kato H, Ohta A, Kobayashi S, Ishii S, Sada Y, Kobayashi H, Ohmori S, Kondo A, Katabami T, Fuse J, Fukuda H, Nagai Y, Tanaka Y.

Endocr J. 2012;59(4):345-52. Epub 2012 Feb 2.

15.

Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.

Yokoyama H, Kannno S, Ishimura I, Node K.

Metabolism. 2007 Nov;56(11):1458-63.

PMID:
17950094
16.

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.

Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C.

Diabetes Care. 1997 May;20(5):687-91.

PMID:
9135927
17.

Dietary treatment with rice containing resistant starch improves markers of endothelial function with reduction of postprandial blood glucose and oxidative stress in patients with prediabetes or newly diagnosed type 2 diabetes.

Kwak JH, Paik JK, Kim HI, Kim OY, Shin DY, Kim HJ, Lee JH, Lee JH.

Atherosclerosis. 2012 Oct;224(2):457-64. doi: 10.1016/j.atherosclerosis.2012.08.003. Epub 2012 Aug 27.

PMID:
22954674
18.

Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.

Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD.

Diabetes Care. 1998 Mar;21(3):416-22.

PMID:
9540025
19.

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.

Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA.

Diabet Med. 1998 Aug;15(8):657-60.

PMID:
9702468
20.
Items per page

Supplemental Content

Write to the Help Desk